Klebsiella Infections Pipeline: 7+ Companies Targeting Multi-Drug Resistance with Novel Antimicrobials and Phage Therapy | DelveInsight

With rising concerns over antibiotic-resistant Klebsiella strains, more than 7 companies are actively developing cutting-edge therapies, including Nosopharm, Debiopharm, and Locus Biosciences. The Klebsiella infections pipeline spans novel antibiotics, monoclonal antibodies, bacteriophage therapy, and immunotherapies. Efforts are particularly focused on carbapenem-resistant Klebsiella pneumoniae (CRKP), an urgent threat per WHO. The pipeline reflects a crucial shift toward precision antimicrobials and host-directed therapies to overcome resistance and reduce mortality in nosocomial infections.

DelveInsight's "Klebsiella Infections Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Klebsiella infections market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Klebsiella infections drugs, the Klebsiella infections pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Explore the full pipeline analysis for Klebsiella infections and uncover key opportunities @ https://www.delveinsight.com/report-store/lewy-body-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Klebsiella Infections Pipeline Report
• DelveInsight's Klebsiella infections pipeline analysis depicts a strong space with 7+ active players working to develop 7+ pipeline drugs for Klebsiella infections treatment.
• The leading Klebsiella infections companies include Nosopharm, Debiopharm, Locus Biosciences, Inc., Inventprise, and others are evaluating their lead assets to improve the Klebsiella infections treatment landscape.
• Key Klebsiella infections pipeline therapies in various stages of development include NOSO-502, Debio 1454, LBP-KP01, IVT Klebsiella, and others.
• In March 2025, GSK plc announced that the FDA approved BLUJEPA (gepotidacin) for treating uncomplicated urinary tract infections (uUTIs) in female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.
• In February 2025, the FDA approved aztreonam and avibactam (EMBLAVEO; AbbVie) as the first fixed-dose intravenous monobactam/β-lactamase inhibitor combination, alongside metronidazole (METROGEL; Galderma Labs), for patients aged 18 and older with limited treatment options for complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria like Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
• In October 2024, Iterum Therapeutics plc announced FDA approval for ORLYNVAH (sulopenem etzadroxil and probenecid) to treat uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited oral antibacterial options. This is the first approved indication for ORLYNVAH and Iterum's first FDA-approved product.

Request a sample and discover the recent breakthroughs happening in the Klebsiella infections pipeline landscape @ https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Klebsiella Infections Overview
Klebsiella is a type of bacteria commonly found in the environment and in the human digestive tract, where it typically causes no harm. However, certain strains-mainly Klebsiella pneumoniae and Klebsiella oxytoca-can lead to serious infections, particularly in hospital or long-term care settings, accounting for up to 8% of hospital-acquired infections in the U.S. Individuals with weakened immune systems or those using medical devices like catheters or ventilators are at higher risk. Transmission occurs through direct contact with contaminated hands or surfaces, not through the air, and is often facilitated by poor hand hygiene among healthcare workers.

Symptoms vary depending on the site of infection; in pneumonia cases, they may include fever, cough, chest pain, breathing difficulties, and thick, reddish mucus. Diagnosis typically involves lab tests of blood, urine, sputum, or imaging studies like chest X-rays. Treatment relies on antibiotics, with selection guided by lab testing to determine the most effective drug, commonly including cephalosporins or fluoroquinolones, sometimes combined with aminoglycosides. Antibiotic resistance is a growing concern, making some infections more difficult to treat.

Find out more about Klebsiella infections medication @ https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Klebsiella Infections Treatment Analysis: Drug Profile
NOSO-502: Nosopharm
NOSO-502 is Nosopharm's first clinical candidate from a novel class of antibiotics known as odilorhabdins, derived from Xenorhabdus bacteria. It is designed to treat severe hospital-acquired infections caused by multidrug-resistant Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp. The drug works by inhibiting bacterial ribosomes through a new mechanism of action and is effective against Carbapenem-Resistant Enterobacteriaceae (CRE), regardless of their carbapenemase profile. NOSO-502 is currently in the preclinical stage for Klebsiella infection treatment.

Debio 1454: Debiopharm
Debio 1454 is an investigational antibiotic targeting a range of enteric bacteria, such as Acinetobacter baumannii, Enterobacter spp., Klebsiella pneumoniae, and E. coli. Supported by CARB-X funding in 2019, this program focuses on combating multidrug-resistant pathogens, particularly A. baumannii, a leading cause of nosocomial pneumonia. The drug is currently in the discovery stage for the treatment of Klebsiella infections.

Learn more about the novel and emerging Klebsiella infections pipeline therapies @ https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Klebsiella Infections Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Klebsiella Infections Pipeline Report
• Coverage: Global
• Key Klebsiella Infections Companies: Nosopharm, Debiopharm, Locus Biosciences, Inc., Inventprise, and others.
• Key Klebsiella Infections Pipeline Therapies: NOSO-502, Debio 1454, LBP-KP01, IVT Klebsiella, and others.

Dive deep into rich insights for drugs used for Klebsiella infections treatment; visit @ https://www.delveinsight.com/report-store/klebsiella-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Klebsiella Infections Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Klebsiella Infections Pipeline Therapeutics
6. Klebsiella Infections Pipeline: Late-Stage Products (Phase III)
7. Klebsiella Infections Pipeline: Mid-Stage Products (Phase II)
8. Klebsiella Infections Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.